Home > Insider Trading > Filing (0001437749-25-022862)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1645469	Monopar Therapeutics	MNPR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1235470	M Christopher Starr	1000 Skokie Blvd Suite 350 Wilmette IL 60091		Yes	No	No	No

Transaction Summary

Sold:	16,800 shares	Avg. Price: $40.00	Total Value: $672,020.16
Number of Shares After Transactions:	5,173 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-07-14	16,800	$0.01	21,973	No	4	X	Direct
Common Stock	Disposition	2025-07-14	16,800	$40.00	5,173	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options	Disposition	2025-07-14	16,800	$0.00	16,800	$0.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2026-04-04	No	4	X	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	9,880	Indirect	See Footnote

Footnotes

This transaction involved a cash exercise of stock options.
The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
9,880 shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee
Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Starr on April 4, 2016, for his services as a director of Monopar Therapeutics. The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter.